Cipla launches leuprolide acetate injection depot 22.5 mg in US
Cipla Limited and its wholly owned subsidiary Cipla USA Inc., has announced the launch of leuprolide acetate injection depot 22.5mg. The product was approved by the United States Food and Drug Administration (FDA) based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway. Leuprolide acetate injection depot contains 22.5 mg of leuprolide acetate for 3-month administration given as a single dose injection. It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe containing 2ml 0.8% mannitol solution and an easy-to-use Mixject transfer device for a single dose injection. It is indicated for palliative treatment of advanced prostate cancer. Arunesh Verma, CEO
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
